Viral and microbial targets

Viral and microbial targets encompass a diverse array of molecular entities within pathogenic organisms, including viruses, bacteria, fungi, and protozoa, that are utilized for the development of anti-infective therapies (NCBI, 2023). These targets typically involve essential biological processes such as nucleic acid replication, protein synthesis, and cell wall or membrane maintenance, which are distinct from human physiological processes to minimize host toxicity (StatPearls, 2023). For instance, bacterial targets often include the 30S or 50S ribosomal subunits and peptidoglycan synthesis enzymes, while viral targets frequently involve proteases, integrases, or polymerases (Nature Reviews Drug Discovery, 2021). The primary goal of interacting with these targets is to inhibit the pathogen's growth or replication, thereby allowing the host's immune system to clear the infection. However, the clinical utility of drugs hitting these targets is frequently compromised by the emergence of antimicrobial resistance (AMR), a global health threat driven by genetic mutations and horizontal gene transfer in microbial populations (WHO, 2023). Because this term represents a high-level category rather than a specific protein or gene, it is generally considered too broad for precise pharmacological modeling or drug-target interaction mapping.

Other names

Pathogen targetsAntimicrobial targetsAntiviral targetsMicrobial proteinsInfectious agent targets

Inhibition of essential pathogen-specific biochemical pathways, including cell wall synthesis, protein translation, and viral genome replication, to halt infection and facilitate pathogen clearance.